PTK2 and melanoma: This discovery paves the way for a possible therapeutic application in AMBRA1-deficient melanomas of FAK1 inhibitors, which are already exploited in preclinical models of melanoma with acquired resistance to BRAFi49, and in clinical trials for solid tumors42,50,51.